Whitepaper: Accelerate biologics development via innovation
Posted: 29 November 2021 | Thermo Fisher Scientific | No comments yet
This whitepaper provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
For most pharmaceutical and biotech companies rising to the challenges of biologics development, this means identifying trusted partners who can provide access to innovative technologies and methodologies, sufficient manufacturing capacity, deep expertise in navigating regulatory channels, and the operational efficiencies to accelerate speed to market. This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly.
Related content from this organisation
- Safety reporting in clinical trials: six core considerations for success
- ebook: Twin-screw extrusion for pharmaceutical applications
- Biopharmaceuticals contributing to manufacturing outsourcing trend
- Biologics driving continuous bioprocessing market expansion
- Mycoplasma testing market expected to value nearly $2 million by 2031
Related topics
Biologics, Biopharmaceuticals, Biosimilars, Drug Delivery Systems, Excipients, Formulation, Freeze Drying, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Microbiology, Outsourcing, Packaging, QA/QC, Regulation & Legislation, Research & Development (R&D), Stem Cells, Supply Chain, Vaccines
